(UroToday.com) According to the EAU guidelines, the treatment recommendations for high risk non-muscle invasive bladder cancer (NMIBC) include full dose BCG instillations for 1-3 years or radical cystectomy.
BCG reduces the risk of progression in NMIBC, but 30% of T1G3 will require deferred radical cystectomy. In T1G3, five-year disease-related death after BCG occurs in 11.3% of patients.